| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.
|
Ann Oncol
|
2002
|
1.74
|
|
2
|
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
|
Cancer
|
1994
|
1.55
|
|
3
|
Ras family genes: an interesting link between cell cycle and cancer.
|
J Cell Physiol
|
2002
|
1.29
|
|
4
|
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
|
Ann Oncol
|
2005
|
1.21
|
|
5
|
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
|
Ann Oncol
|
2006
|
1.18
|
|
6
|
On the possible causes of the release of material absorbing at 260 m-mu by streptomycin treated E. coli cells (K 12 and B).
|
J Antibiot (Tokyo)
|
1967
|
1.08
|
|
7
|
[Release of nucleotides and integrity of the bacterial membrane (E. coli K 12)].
|
Antibiotica
|
1966
|
1.06
|
|
8
|
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
|
Ann Oncol
|
2005
|
1.05
|
|
9
|
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
|
Ann Oncol
|
2006
|
1.03
|
|
10
|
Cathepsin D in the malignant progression of neoplastic diseases (review).
|
Anticancer Res
|
1992
|
1.01
|
|
11
|
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
|
J Clin Oncol
|
1988
|
1.01
|
|
12
|
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features.
|
Ann Oncol
|
2007
|
0.95
|
|
13
|
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients.
|
Ann Oncol
|
2005
|
0.95
|
|
14
|
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
|
J Cancer Res Clin Oncol
|
2002
|
0.94
|
|
15
|
Cathepsin D, B and L circulating levels as prognostic markers of malignant progression.
|
Anticancer Res
|
1996
|
0.93
|
|
16
|
Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications.
|
Oncology
|
1997
|
0.92
|
|
17
|
Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity.
|
Eur J Cancer
|
1994
|
0.91
|
|
18
|
Single agent paclitaxel in advanced squamous cell head and neck carcinoma.
|
Eur J Cancer
|
1996
|
0.90
|
|
19
|
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
|
Cancer
|
1996
|
0.89
|
|
20
|
Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis.
|
Eur J Clin Chem Clin Biochem
|
1996
|
0.87
|
|
21
|
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis.
|
Ann Oncol
|
2007
|
0.86
|
|
22
|
Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma.
|
Clin Cancer Res
|
2000
|
0.86
|
|
23
|
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
|
Oncol Rep
|
2010
|
0.85
|
|
24
|
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma.
|
J Chemother
|
1993
|
0.83
|
|
25
|
Emotional expression and coping style in female breast cancer.
|
Ann Oncol
|
2007
|
0.83
|
|
26
|
Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis.
|
Pancreas
|
1997
|
0.83
|
|
27
|
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
|
Anticancer Drugs
|
1997
|
0.83
|
|
28
|
Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
|
Cancer
|
1995
|
0.82
|
|
29
|
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.
|
Ann Oncol
|
2007
|
0.81
|
|
30
|
Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity.
|
Arzneimittelforschung
|
1971
|
0.81
|
|
31
|
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
|
Ann Oncol
|
2006
|
0.81
|
|
32
|
Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma.
|
Tumori
|
1994
|
0.81
|
|
33
|
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
|
Ann Oncol
|
2011
|
0.81
|
|
34
|
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
|
Br J Cancer
|
1997
|
0.81
|
|
35
|
A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy.
|
Anticancer Res
|
1994
|
0.80
|
|
36
|
Haemopoietic effects of 7 alpha, 17 beta dimethyltestosterone.
|
Pharmacol Res Commun
|
1979
|
0.80
|
|
37
|
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience.
|
Eur J Cancer
|
2011
|
0.80
|
|
38
|
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
|
Ann Oncol
|
2000
|
0.79
|
|
39
|
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
|
J Chemother
|
2005
|
0.79
|
|
40
|
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
|
Int J Gynecol Cancer
|
2006
|
0.79
|
|
41
|
A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy.
|
J Chemother
|
2006
|
0.79
|
|
42
|
Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.
|
Br J Cancer
|
1990
|
0.79
|
|
43
|
A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Eur J Cancer
|
1993
|
0.79
|
|
44
|
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases.
|
Eur J Surg Oncol
|
1995
|
0.79
|
|
45
|
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).
|
Ann Oncol
|
2007
|
0.79
|
|
46
|
Lysosomal alterations in heart and liver of mice treated with doxorubicin.
|
Cancer Chemother Pharmacol
|
1985
|
0.79
|
|
47
|
Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer.
|
Br J Cancer
|
1996
|
0.79
|
|
48
|
Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications.
|
Med Res Rev
|
1993
|
0.78
|
|
49
|
Hereditary common cancers: molecular and clinical genetics.
|
Anticancer Res
|
2001
|
0.78
|
|
50
|
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma.
|
Cancer Invest
|
1992
|
0.78
|
|
51
|
Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
|
Anticancer Res
|
1990
|
0.78
|
|
52
|
Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma.
|
Anticancer Res
|
1993
|
0.78
|
|
53
|
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
|
J Cancer Res Clin Oncol
|
1998
|
0.78
|
|
54
|
Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer.
|
Eur J Cancer
|
1994
|
0.78
|
|
55
|
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
|
Ann Oncol
|
2005
|
0.78
|
|
56
|
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
|
J Cancer Res Clin Oncol
|
1989
|
0.78
|
|
57
|
Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM).
|
Am J Clin Oncol
|
1996
|
0.78
|
|
58
|
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study.
|
Cancer
|
2001
|
0.78
|
|
59
|
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
|
J Cancer Res Clin Oncol
|
1992
|
0.78
|
|
60
|
Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
|
Eur J Gynaecol Oncol
|
1993
|
0.77
|
|
61
|
[Clinical guidelines for the management of gastrointestinal stromal tumors].
|
Clin Ter
|
2006
|
0.77
|
|
62
|
Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy.
|
In Vivo
|
1992
|
0.77
|
|
63
|
Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A.
|
Int J Biochem
|
1988
|
0.77
|
|
64
|
Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease.
|
J Chemother
|
1992
|
0.77
|
|
65
|
Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report.
|
Oncology
|
1995
|
0.77
|
|
66
|
Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors.
|
In Vivo
|
1994
|
0.76
|
|
67
|
Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.
|
Urol Res
|
1976
|
0.76
|
|
68
|
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
|
Br J Cancer
|
2005
|
0.76
|
|
69
|
Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma.
|
Tumori
|
1990
|
0.76
|
|
70
|
Evaluation of antitumor and antimetastatic activity of pepstatin A in some experimental tumor models.
|
J Chemother
|
1989
|
0.76
|
|
71
|
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM).
|
Am J Clin Oncol
|
1999
|
0.76
|
|
72
|
A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.
|
Clin Ter
|
1999
|
0.76
|
|
73
|
Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma.
|
Eur J Cancer
|
1996
|
0.75
|
|
74
|
Usefulness of oral medroxyprogesterone acetate in the management of cancer-related cachexia-anorexia syndrome.
|
Oncol Rep
|
1996
|
0.75
|
|
75
|
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
|
Int J Biol Markers
|
2002
|
0.75
|
|
76
|
Effects of amsacrine (m-AMSA), a new aminoacridine antitumor drug, on the rabbit heart.
|
Cancer Treat Rep
|
1983
|
0.75
|
|
77
|
Cathepsin-d activity levels in colorectal-cancer - correlation with cathepsin-B and cathepsin-L and other biological and clinical-parameters.
|
Int J Oncol
|
1994
|
0.75
|
|
78
|
Changes of the intracellular water space produced by antibacterial drugs in relation to membrane permeability and membrane lesions.
|
Br J Pharmacol
|
1968
|
0.75
|
|
79
|
Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas.
|
Am J Clin Oncol
|
1994
|
0.75
|
|
80
|
Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance.
|
Cancer
|
1995
|
0.75
|
|
81
|
[Analysis of some factors responsible for the bactericidic action and resistance to streptomycin of the E. coli cells].
|
G Ital Chemioter
|
1975
|
0.75
|
|
82
|
Pharmacological modulation of 5-fluorouracil and its clinical implications: an overview.
|
In Vivo
|
1994
|
0.75
|
|
83
|
Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study.
|
J Chemother
|
1991
|
0.75
|
|
84
|
Nephrotoxic effects of pepstatin A. An histoenzymologic study.
|
Pharmacol Res
|
1991
|
0.75
|
|
85
|
Experimental techniques for testing the sensitivity of bladder tumours to antineoplastic drugs.
|
Urol Res
|
1973
|
0.75
|
|
86
|
The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse.
|
Tumori
|
1987
|
0.75
|
|
87
|
A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma.
|
Acta Oncol
|
1994
|
0.75
|
|
88
|
[Absorption of drugs through the bladder. Experiences with antineoplastic agents].
|
Recenti Prog Med
|
1975
|
0.75
|
|
89
|
Cisplatin plus vp16 as salvage treatment for advanced breast-carcinoma resistant or recurrent after 1st line chemotherapy for metastatic disease.
|
Oncol Rep
|
1995
|
0.75
|
|
90
|
Tumor markers in urogynaecological tumors.
|
Tunis Med
|
2005
|
0.75
|
|
91
|
A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma.
|
J Chemother
|
1990
|
0.75
|
|
92
|
[Analysis of the factors regulating the penetration of Na2 S35 O-4 in E. coli].
|
Boll Soc Ital Biol Sper
|
1965
|
0.75
|
|
93
|
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
|
Anticancer Drugs
|
1992
|
0.75
|
|
94
|
Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
|
Lung Cancer
|
2001
|
0.75
|
|
95
|
Elf regimen in advanced gastrointestinal malignancies - an analysis of its clinical effectiveness and toxicity.
|
Int J Oncol
|
1994
|
0.75
|
|
96
|
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
|
Anticancer Drugs
|
1996
|
0.75
|
|
97
|
Single agent vinorelbine in the treatment of unresectable lung metastases from colorectal cancer.
|
Oncol Rep
|
1996
|
0.75
|
|
98
|
Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients.
|
Anticancer Res
|
1996
|
0.75
|
|
99
|
Clinical and experimental projects on chemotherapy of bladder tumours.
|
S Afr Med J
|
1974
|
0.75
|
|
100
|
Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.
|
Anticancer Drugs
|
1997
|
0.75
|
|
101
|
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
|
Cancer
|
1997
|
0.75
|
|
102
|
Second line chemotherapy for metastatic colorectal carcinoma.
|
Oncol Rep
|
1996
|
0.75
|
|
103
|
The effectiveness of combination chemotherapy with cisplatinum and etoposide in the treatment of advanced non-small cell lung cancer.
|
J Chemother
|
1989
|
0.75
|
|
104
|
Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma.
|
Anticancer Drugs
|
1996
|
0.75
|
|
105
|
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma.
|
J Chemother
|
1991
|
0.75
|
|
106
|
Antiblastic drug combinations with ifosfamide: an update.
|
Oncology
|
2003
|
0.75
|
|
107
|
Acute myocardial effects of mitoxantrone in the rabbit.
|
Cancer Treat Rep
|
1987
|
0.75
|
|
108
|
Combination chemotherapy with cyclophosphamide, doxorubicin and vincristine in the treatment of stage III-IV small-cell lung cancer.
|
J Chemother
|
1989
|
0.75
|
|
109
|
In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1.
|
Pharmacol Res
|
1991
|
0.75
|
|
110
|
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.
|
J Cancer Res Clin Oncol
|
1991
|
0.75
|
|
111
|
Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
ORL J Otorhinolaryngol Relat Spec
|
1994
|
0.75
|
|
112
|
[Passage of AMP through the membrane of E. coli K 12 in the presence of antibacterial drugs].
|
Antibiotica
|
1968
|
0.75
|
|
113
|
Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma: a multicentric phase II study of the Southern Italy Oncology Group (GOIM).
|
Oncology
|
1996
|
0.75
|
|
114
|
Subcutaneous recombinant-human-erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer.
|
Int J Oncol
|
1992
|
0.75
|
|
115
|
Absorption of drugs from the bladder and intravesical chemotherapy.
|
Urol Res
|
1976
|
0.75
|
|
116
|
Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck.
|
Am J Clin Oncol
|
1995
|
0.75
|